Lilinorm (Hydrocortisone)

Hydrocortisone acts as an agonist at intracellular glucocorticoid receptors. After binding, the receptor complex moves into the cell nucleus and alters gene transcription, increasing anti‑inflammatory protein production while decreasing pro‑inflammatory cytokines, thereby reducing immune activation and swelling.

The appropriate dose of Lilinorm is individualized by the prescribing clinician based on the specific indication, severity of disease, patient weight, age, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber sets the dosage.

Safety data for hydrocortisone in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Clinicians must evaluate each case and discuss potential risks with the patient.

To request Lilinorm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lilinorm delivers hydrocortisone, which has a relatively short half‑life and a potency similar to endogenous cortisol. Compared with longer‑acting agents such as prednisolone or dexamethasone, hydrocortisone offers more physiologic replacement with a lower risk of prolonged systemic effects, making it suitable for adrenal insufficiency and short‑term anti‑inflammatory use.

Lilinorm should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lilinorm is taken orally, usually with water. The exact administration schedule—such as once daily or divided doses—depends on the prescribing clinician’s instructions and the condition being treated.

Serious risks include adrenal suppression if the drug is stopped abruptly, severe hyperglycemia or new‑onset diabetes, opportunistic infections due to immunosuppression, and rare events such as avascular necrosis or severe psychiatric disturbances. Patients should be monitored closely for these complications.

Lilinorm is contraindicated in individuals with known hypersensitivity to hydrocortisone or any excipients in the formulation. Caution is also advised for patients with uncontrolled systemic infections, active tuberculosis, or those receiving systemic antifungal therapy that may interact significantly.